---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-008282"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T01:04:02.036206+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Nuvalent reports net loss of $81.9M for FY22; cash runway into H2 2025

## Summary
- Cash, cash equivalents and marketable securities $472.2M as of Dec 31, 2022; expected to fund operations into H2 2025.
- Net loss of $26.1M in Q4 2022 and $81.9M for full year 2022; R&D expenses $63.7M (FY) vs $35.6M in 2021.
- Pipeline progress: NVL-520 Phase 1 data supportive of best-in-class profile in ROS1+ NSCLC; NVL-655 Phase 1 enrolling; NVL-330 (HER2 exon20) nominated as development candidate.
- Leadership promotions: Henry Pelish to SVP Drug Discovery; John Soglia to SVP Translational Development.

## SEC filing metadata
- accession: 0000950170-23-008282
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000095017023008282/0000950170-23-008282-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000095017023008282/nuvl-20230316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-008282
- JSON: https://secwatch.observer/filing/0000950170-23-008282.json
- Plain text: https://secwatch.observer/filing/0000950170-23-008282.txt

## Key facts
- Earnings Releases
  Nuvalent, Inc. reported financial results for the quarter and year ended December 31, 2022.
  - Period: the quarter and year ended December 31, 2022
  - Result: reported results
  source text: announced its financial results for the quarter and year ended December 31, 2023, and other corporate updates. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1861560/000095017023008282/0000950170-23-008282-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.